PharmaCyte Biotech, Inc. Fair Value Disclosure

NOTE 14 – FAIR VALUE MEASUREMENTS

 

Fair value measurements discussed herein are based upon certain market assumptions and pertinent information available to management as of and during the year ended April 30, 2025 and 2024. The carrying amounts of cash equivalents, other current assets, accounts payable and accrued expenses approximate their fair values at April 30, 2025 and 2024 due to their short-term nature. The fair value of the bifurcated embedded derivative related to the convertible preferred stock was estimated using a Monte Carlo simulation model, which uses as inputs the fair value of the Company’s common stock and guideline companies estimates for the equity volatility and traded volume volatility of our common stock, the time maturity of the convertible preferred stock, the risk-free interest rate for a period of time that approximates the time to maturity, dividend rate, a penalty dividend rate and the probability of default. The fair value of the warrant liability was estimated using the Black Scholes Merton Model which uses as inputs the following weighted average assumptions, as noted above: dividend yield, expected terms in years, equity volatility and risk-free rate.

 

Fair Value on a Recurring Basis

 

The Company follows the guidance in ASC 820 for its financial assets and liabilities that are re-measured and reported and reported at fair at each reporting period, and non-financial assets and liabilities that are re-measured and reported at fair value at least annually. The estimated fair value of the warrant liability and bifurcated embedded derivative represent Level 3 measurements. The following table presents information about the Company’s liabilities that are measured at fair value on a recurring basis at April 30, 2025 and 2024, and indicates the fair value hierarchy of the valuation inputs the Company utilized to determine such fair value:

Schedule of fair value of financial liabilities
Description		Level				April 30, 2025				April 30, 2024
Liabilities:
Warrant liability			3			$	338,000			$	10,784,000
Bifurcated embedded derivative			3			$	–			$	2,184,000

 

The following table sets forth a summary of the change in the fair value of the warrant liability that is measured at fair value on a recurring basis:

Schedule of change in the fair value of the warrant liability
		April 30, 2025
Balance on April 30, 2023		$	–
Issuance of warrants			14,127,000
Change in fair value of warrant liability			(3,343,000	)
Balance on April 30, 2024			10,784,000
Issuance of warrants			–
Change in fair value of warrant liability			(10,446,000	)
Balance on April 30, 2025		$	338,000

 

The following table sets forth a summary of the change in the fair value of the bifurcated embedded derivative liability that is measured on a recurring basis: 

Schedule of embedded derivative liability
		April 30, 2025
Balance on April 30, 2023		$	–
Issuance of convertible preferred stock with bifurcated embedded derivative liability			2,770,000
Change in fair value of bifurcated embedded derivative			(586,000	)
Balance on April 30, 2024			2,184,000
Issuance of convertible preferred stock with bifurcated embedded derivative liability			–
Change in fair value of bifurcated embedded derivative			(2,184,000	)
Balance on April 30, 2025		$	–

 

The fair value of the convertible note receivable using the income approach, which uses as inputs the fair value of debtor’s common stock and estimates for the equity volatility and volume volatility of debtor’s common stock, the time to expiration of the convertible note, the discount rate, the stated interest rate compared to the current market rate, the risk-free interest rate for a period that approximates the time to expiration, and probability of default. Therefore, the estimate of expected future volatility is based on the actual volatility of debtor’s common stock and historical volatility of debtor’s common stock utilizing a lookback period consistent with the time to expiration. The time to expiration is based on the contractual maturity date. The risk-free interest rate is determined by reference to the U.S. Treasury yield curve in effect at the time of measurement for time periods approximately equal to the time to expiration. Probability of default is estimated using the S&P Global default rate for companies with a similar credit rating to debtor’s.

 

The fair values of financial instruments by class as of April 30, 2025 and 2024 are as follows: 

Schedule of fair values of financial instruments by class
		Level				April 30, 2025				April 30, 2024
Financial Assets
Marketable equity securities			1			$	366,316			$	–
Money market account			1			$	76,287			$	3,183,173
Convertible note receivable – investment in debt security - Femasys			3			$	3,696,000			$	2,755,000
Warrant asset - Femasys			3			$	3,061,000			$	5,152,000
Investment in preferred stock - TNF			3			$	22,474,000			$	–
Warrant asset - TNF			3			$	8,618,000			$	–

 

Assumptions used in the valuation of the Level 3 assets include time to expiration, discount rate, risk-free rate, volatility and probability of default.